



EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
14.01.1988 Bulletin 1988/03

(51) Int Cl.⁶: G01N 33/53

(86) International application number:
PCT/US88/01941

(21) Application number: 88907519.8

(87) International publication number:
WO 89/00692 (26.01.1989 Gazette 1989/03)

(22) Date of filing: 07.06.1988

(54) **SECOND GENERATION MONOCLONAL ANTIBODIES HAVING BINDING SPECIFICITY TO TAG-72 AND HUMAN CARCINOMAS AND METHODS FOR EMPLOYING THE SAME**

MONOKLONALE ANTIKÖRPER DER ZWEITEN GENERATION MIT BINDUNGSSPEZIFITÄT FÜR TAG-72 UND MENSCHLICHE KARZINOME SOWIE METHODEN ZU IHRER ANWENDUNG

ANTICORPS MONOCLONAUX DE SECONDE GENERATION AYANT UNE SPECIFICITE DE LIAISON SUR TAG-72 ET DES CARCINOMES HUMAINS, ET PROCEDE D'UTILISATION DE CES ANTICORPS

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(30) Priority: 15.07.1987 US 73685

(43) Date of publication of application:
31.10.1990 Bulletin 1990/44

(73) Proprietor: THE UNITED STATES OF AMERICA as
represented by the Secretary United States
Department of Commerce
Springfield, Virginia 22161 (US)

(72) Inventors:
• SCHLOM, Jeffrey
Potomac, MD 20854 (US)
• COLCHER, David
Potomac, MD 20854 (US)

(74) Representative: Lord, Hilton David et al
MARKS & CLERK,
57-60 Lincoln's Inn Fields
London WC2A 3LS (GB)

(56) References cited:
US-A- 4 361 544 US-A- 4 634 586

• CANCER, vol. 57, no. 3, 1986, Philadelphia, PA
(US); J. LUNDY

- BIOLOGICAL ABSTRACTS, vol. 81, no. 2, 15 January 1986, Philadelphia, PA (US); S.C. LOTTICH: "Tumor-associated Antigen TAG-72; Correlation of Expression in Primary and Metastatic Breast Cancer Lesions" see page 679, column 1, the abstract No. 15748, Breast Cancer Res. Treat. 1985, 6(1), 49-56 (Eng).
- BIOLOGICAL ABSTRACTS, vol. 82, no. 3, 01 August 1986, Philadelphia, PA (US); A. J. PATERSON, p. 685, no. 36028/
- CLINICAL CHEMISTRY, vol. 27, no. 11, 1981, Winston-Salem, NC (US); E.D. SEVIER, pp. 1799-1800/
- JNCI, vol. 76, no. 6, June 1986, Washington, DC (US); F. GORSTEIN, pp. 995- 1003
- R. LEVY, "Monoclonal Antibodies in Approaches to Tumor Immunology", Summary of Minisymposium Presented by the American Association of Immunologists, 66th Annual Meeting of the Federation of American Societies for Experimental Biology, New Orleans, LA (US), 16 April 1982; "Tumor Therapy with Monoclonal Antibodies", pp. 2655-2656
- N. Ohuchi, "In vivo Application of Monoclonal Antibodies in the Management of Human Carcinomas", Medline, Index Medicus, Gan To Kagaku Ryoho (Japan) April 1988, Volume 15, No. 4, 1109-1114

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- H. Hedlin "Tumor Localization of CEA Containing Human Tumors in Nude Mice by Means of Monoclonal Anti-CEA Antibodies", M dline, Index Medicus, Int. J. Cancer, 15 November 1982, Volume 30, No. 5, 547-552

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Description

FIELD OF THE INVENTION

The present invention relates to second generation monoclonal antibodies having binding specificity to a tumor associated glycoprotein having an approximate molecular weight of $>10^6$ d (hereinafter "TAG-72") and human carcinomas, and methods for employing the same.

BACKGROUND OF THE INVENTION

Numerous monoclonal antibodies have been developed which have binding specificity for a variety of human carcinomas (see Schlom, et al., "Important Advances in Oncology", Philadelphia, PA, J.B. Lippincott Co., Vol. 1, pp. 170-192 (1984) and Schlom, *Cancer Res.*, **46**:3225-3238 (1986)). One of these monoclonal antibodies designated B72.3 (see Colcher, et al., *Proc. Natl. Acad. Sci. USA*, **78**:3199-3203 (1981) and U.S. Patents Nos. 4,522,918 and 4,612,282), is a murine IgG₁, and was developed using a human breast carcinoma extract as the immunogen. Monoclonal antibody B72.3 is produced by hybridoma B72.3 (ATCC No. HB-8108) and has been extensively studied. Monoclonal antibody B72.3 has been shown to be distinct from other known monoclonal antibodies on the basis of: (1) its binding specificity to TAG-72 (see Johnson, et al., *Cancer Res.*, **46**:857-859 (1986)); (2) its binding specificity to various types of human carcinoma tissues, including breast, ovarian, lung, colorectal, endometrial, and pancreatic carcinoma tissues (see Nuti, et al., *Intl. J. Cancer*, **29**:539-545 (1982); Stramignoni, et al., *Intl. J. Cancer*, **31**:543-552 (1982); Thor, et al., *J. Natl. Cancer Inst.*, **76**:995-1006 (1986); and Thor, et al., *Cancer Res.*, **46**:3118-3124 (1986)); (3) its lack of binding specificity to normal adult human tissues (see Nuti, et al., *Intl. J. Cancer*, **29**:539-545 (1982); Stramignoni, et al., *Intl. J. Cancer*, **31**:543-552 (1983); Thor, et al., *J. Natl. Cancer Inst.*, **76**:995-1006 (1986); and Thor, et al., *Cancer Res.*, **46**:3118-3124 (1986)); (4) its ability to detect TAG-72 in serum (see Paterson, et al., *Intl. J. Cancer*, **37**:659-666 (1986) and Klug, et al., *Intl. J. Cancer*, **38**:661-669 (1986)); (5) its ability to detect carcinoma cells in human effusions and fine needle aspiration biopsies (see Szpak, et al., *Acta Cytologica*, **28**:356-367 (1984); Johnston, et al., *Cancer Res.*, **45**:1894-1900 (1986); Szpak, et al., *Am. J. Path.*, **122**:252-260 (1986); Johnston, et al., *Human Path.*, **17**:501-513 (1986); Martin, et al., *Am. J. Clin. Path.*, **86**:10-18 (1986); Nuti, et al., *Intl. J. Cancer*, **37**:493-498 (1986); and Johnston, et al., *Cancer Res.*, **46**:6462-6470 (1986)); and (6) its binding specificity and prolonged binding to human carcinomas both in experimental animal systems (see Kennan, et al., *J. Nucl. Med.*, **25**:1197-1203 (1984) and Colcher, et al., *Cancer Res.*, **44**:5744-5751 (1984)) and in clinical trials (see Colcher, et al., *Cancer Res.*, **47**:1185-1189 (1987) and Esteban, et al., *Intl. J. Cancer*, **39**:50-58 (1987)).

However, monoclonal antibody B72.3 is disadvantageous in that (1) B72.3 does not have binding specificity to every human carcinoma tissue of a particular type, e.g., to every ovarian, colon carcinoma tissue, etc. (See Nuti, et al., *Intl. J. Cancer*, **29**:539-545 (1982); Stramignoni, et al., *Intl. J. Cancer*, **31**:543-552 (1983); Thor, et al., *J. Natl. Cancer Inst.*, **76**:995-1006 (1986); Thor, et al., *Cancer Res.*, **46**:3118-3124 (1986); and Hand, et al., *Cancer Res.*, **43**:728-735 (1983)); (2) B72.3 does not have binding specificity to all carcinoma cells within a given human carcinoma mass (see Nuti, et al., *supra.*; Stramignoni, et al., *supra.*; Thor, et al., *J. Natl. Cancer Inst.*, **76**:995-1006 (1986); Thor, et al., *Cancer Res.*, **46**:3118-3124 (1986); and Hand, et al., *supra.*), (3) B72.3 does not have binding specificity to most human carcinoma cell lines in culture (see Hand, et al., *supra.*; Hand et al., *Cancer Res.*, **45**:833-840 (1985); and Friedman et al., *Cancer Res.*, **45**:5648-5655 (1985)); (4) it is difficult to obtain highly immunoreactive F(ab')₂, F(ab') and F(ab) fragments from B72.3, such fragments being necessary for efficient *in vivo* immunodiagnostic and therapeutic applications; and (5) since B72.3 is of the IgG₁ isotype, it is difficult to conduct monoclonal antibody effector cell mediated cytotoxicity or complement mediated cytotoxicity studies using B72.3 (IgG_{2a}, IgG_{2b} or IgM isotypes being more efficient for these applications).

DEPOSIT OF THE BIOLOGICAL MATERIAL OF THIS INVENTION

Viable samples of Hybridoma Cell Lines CC 83; CC 92; CC 11; MATAG 12; CC 30; CC 46; CC 49; and CC 15; have been deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD. 20852, on June 26, 1987, and respectively have the following ATCC designations HB 9453, HB 9454, HB 9455, HB 9456, HB 9457, HB 9458, HB 9459, and HB 9460.

SUMMARY OF THE INVENTION

Accordingly, an object of the present invention is to provide monoclonal antibodies which have binding specificity to a variety of human carcinomas, including human carcinomas of a given type for which B72.3 essentially has no binding specificity.

Another object of the present invention is to provide monoclonal antibodies having high binding affinity for TAG-72 and human carcinomas.

A further object of the present invention is to provide monoclonal antibodies from which highly immunoreactive F(ab')₂, F(ab') and F(ab) fragments can be easily obtained for use in in vivo immunodiagnosis and therapy of human carcinomas.

A still further object of the present invention is to provide monoclonal antibodies from which recombinant antibodies can be obtained for use in in vivo immunodiagnosis and therapy of human carcinomas.

An additional object of the present invention is to provide monoclonal antibodies of the IgG_{2a}, IgG_{2b} and IgM isotypes which have binding specificity for human carcinomas for use in conducting monoclonal antibody effector cell mediated cytotoxicity or complement mediated cytotoxicity studies.

Still an additional object of the present invention is to provide methods for diagnosing in vitro and in vivo human carcinomas employing these monoclonal antibodies.

Other objects and advantages of the present invention will become apparent from the Detailed Description of the Invention presented hereunder.

The above and various other objects and advantages of the present invention are achieved by the second generation monoclonal antibodies of the present invention which have binding affinity to both TAG-72 and to LS-174T antigen (a).

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described.

As used herein, the expression "second generation monoclonal antibodies" means monoclonal antibodies produced using, as the immunogen, an antigen which has been affinity purified with a first generation monoclonal antibody. As used herein, the expression "first generation monoclonal antibody" means a monoclonal antibody produced using, as the immunogen, a crude cell extract.

The term "substantially" as used herein means almost wholly or to a large extent, but not entirely.

LS-174T (ATCC No. CRL-188) is a variant of the LS180 (ATCC No. CRL-187) colon adenocarcinoma line. It is more easily subcultivated than the parent line. It is tumorigenic in nude mice. The karyotype is similar to that of LS180 with a missing X chromosome in a majority of the cells. Electron microscopic studies reveal abundant microvilli and intracytoplasmic mucin vacuoles (see Torn, et al., *In Vitro*, 12:180-191 (1976)).

TAG-72 is an antigen found in the LS-174T tumor cell line. Monoclonal antibody B72.3 binds to a high molecular weight tumor associated glycoprotein identified as TAG-72. Data has been presented as described in Johnson, et al., *Cancer Res.*, 46:850-857 (1986), to characterize the TAG-72 molecule as a mucin. This conclusion is based on the following observations: (a) TAG-72 has a high molecular weight (>1 x 10⁶) as shown by its exclusion from a Sepharose CL-4B™ column; (b) the density of TAG-72 determined by equilibrium centrifugation in CsCl was 1.45 gm/ml, indicating a heavily glycosylated glycoprotein; (c) TAG-72 demonstrates a change in migration after neuraminidase digestion, indicating that it is a heavily sialylated molecule with an abundance of O-glycosidically linked oligosaccharides characteristic of mucins; (d) blood group antigens commonly found on mucins are found on affinity-purified TAG-72; and (e) chondroitinase ABC digestion had no effect on TAG-72, thus demonstrating that the TAG-72 epitope is not expressed on a chondroitin sulfate proteoglycan.

More specifically, the above-described objects of the present invention have been achieved by the second generation monoclonal antibodies of the present invention, immunoreactive fragments or recombinants thereof which have binding specificity to TAG-72 and to human carcinomas, including human carcinomas to which antibody B72.3 has minimal binding specificity and with minimal binding specificity to normal adult human tissues. The term "minimal" means the least possible or substantially inconsequential.

To another embodiment, the above-described objects of the present invention have been achieved by a method for diagnosing a human carcinoma or metastases thereof comprising:

- (a) obtaining a body sample, such as body fluid, tissue or biopsy from a patient;
- (b) contacting the body sample material with a second generation monoclonal antibody of the present invention, an immunoreactive fragment or a recombinant thereof;
- (c) determining the level of binding of second generation monoclonal antibody, immunoreactive fragment or recombinant thereof to the body sample material; and
- (d) comparing the amount of second generation monoclonal antibody, immunoreactive fragment or recombinant thereof bound to substances present in the body sample to a control sample or to a predetermined base level, so that a binding greater than the control level is indicative of the presence of human carcinomas or metastases thereof.

In a still further embodiment, the above-described objects of the present invention have been achieved by the use in therapy of, a pharmaceutically effective amount of a second generation monoclonal antibody of the present invention or an immunoreactive fragment or recombinant thereof conjugated to a therapeutic agent.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic diagram of: (1) the differential binding specificities of the CC and MATAG monoclonal antibodies of the present invention to LS-174T colon carcinoma cells (ATCC No. CRL-188) in a competition radioimmunoassay (hereinafter "RIA") with B72.3; (2) the isotypes of the CC and MATAG monoclonal antibodies of the present invention; and (3) the binding specificity of the CC and MATAG monoclonal antibodies of the present invention to various colon carcinomas in a solid phase RIA (hereinafter "SPRIA").

Figure 2 is an analysis of the binding specificity of monoclonal antibody CC41 to LS-174T colon carcinoma cell extract in a competition RIA with B72.3. Figure 2B is a quantitative analysis of the binding specificities of monoclonal antibodies B72.3 and CC41 to LS-174T colon carcinoma cell line extract (LS) and a breast carcinoma biopsy extract (Br. Ca.) in a SPIRA.

Figure 2C is an analysis of the binding specificity of monoclonal antibody CC60 to LS-174T colon carcinoma cell extract in a competition RIA with B72.3. Figure 2D is a quantitative analysis of the binding specificities of monoclonal antibodies B72.3 and CC60 to LS-174T colon carcinoma cell line extract (LS) and a breast biopsy extract (Br. Ca.) in a SPIRA.

Figure 2E is an analysis of the binding specificity of monoclonal antibody CC83 to LS-174T colon carcinoma cell extract in a competition RIA with B72.3. Figure 2F is a quantitative analysis of the binding specificities of monoclonal antibodies B72.3 and CC83 to LS-174T colon carcinoma cell line extract (LS) and a breast carcinoma biopsy extract (Br. Ca.) in a SPIRA.

Figure 2G is an analysis of the binding specificity of monoclonal antibody CC49 to LS-174T colon carcinoma cell extract in a competition RIA with B72.3.

Figure 2H is a quantitative analysis of the binding specificities of monoclonal antibodies B72.3 and CC49 to LS-174T colon carcinoma cell line extract (LS) and a breast carcinoma biopsy extract (Br. Ca.) in a SPIRA.

Figure 3 is an analysis of a competition RIA with CC49, wherein ^{125}I -labelled CC49 monoclonal antibody was reacted with LS-174T colon carcinoma cell extract and purified CC30, CC46, CC49, CC83 and B72.3 were used as competing antibodies.

Figure 4A is an analysis of the *in vivo* targeting of a LS-174T colon carcinoma xenograft with monoclonal antibody CC11.

Figure 4B is an analysis of the *in vivo* targeting of a LS-174T colon carcinoma xenograft with monoclonal antibody CC46.

DETAILED DESCRIPTION OF THE INVENTION

I. Characteristics of the Monoclonal Antibodies

The monoclonal antibodies specifically developed in the present invention, designated CC1 to CC92 (IgG monoclonal antibodies) and MATAG 1 to MATAG 18 (IgM monoclonal antibodies) (see Figure 1) all have binding specificity to TAG-72 and numerous types of human carcinomas (including breast, ovarian, lung, colorectal, endometrial and pancreatic carcinomas), and are different from B72.3 in that they:

- (1) have binding specificity to more human carcinomas than B72.3 while still maintaining essentially no specificity to normal adult human tissues;
- (2) have a higher binding affinity for TAG-72 than B72.3, i.e., on the order of greater than $3 \times 10^9 \text{M}^{-1}$, preferably greater than $8 \times 10^9 \text{M}^{-1}$ and consequently bind human carcinomas *in vivo* at a higher efficiency;
- (3) exhibit a 50% or more efficiency than B72.3 in targeting human carcinomas *in situ* (i.e., 50% more injected dose/gram tumor than B72.3 and preferably greater than 100% more injected dose/gram tumor than B72.3);
- (4) can be easily fragmented with pepsin to obtain F(ab')_2 , F(ab)' and F(ab) fragments that are highly immunoreactive; and
- (5) include monoclonal antibodies of the IgG_{2a} , IgG_{2b} , and IgM isotypes so they can more efficiently be used in monoclonal antibody targeted effector cell mediated cytotoxicity or complement mediated cytotoxicity studies.

The development of the CC and MATAG monoclonal antibodies of the present invention also now makes feasible the use of double determinant RIAs (hereinafter "DDRIA"s) for more efficient detection of human carcinoma antigens in body fluids and biopsies of cancer patients.

II. Production of the Monoclonal Antibodies

The CC and MATAg monoclonal antibodies of the present invention are produced by immunizing mice (or other animals such as rats, rabbits, goats, and humans) with purified TAG-72 obtained from various xenografts, such as LS-174T human colon carcinoma xenografts prepared using LS-174T carcinoma cells (ATCC No. CRL-188) and OVCAR-3 human ovarian cancer xenografts, prepared using OVCAR-3 carcinoma cells (see Hamilton, et al., Cancer Res., **43**: 5379-5389 (1983)).

TAG-72 is purified from the xenografts by methods well known in the art. More specifically, by the following steps: (1) breaking the cells; (2) centrifuging and/or filtering to remove cellular debris; (3) carrying out sizing column chromatography to obtain proteins having a molecular weight of $>10^6$ d, i.e., the molecular weight of TAG-72; and then (4) carrying out B72.3 affinity column chromatography to obtain the desired TAG-72 (see Paterson, et al., Intl. J. Cancer, **37**:659-666 (1986)).

Immunizing the animals, e.g., mice, with the purified TAG-72, isolating the immunized cells, fusing the immunized cells with mouse myeloma cells (or myeloma cells of other species such as rats, rabbits, goats and humans), all of which are well known in the art and readily available, and culturing the resulting fused cells under conditions which allow for growth of hybridomas, are all conducted by methods well known or readily determined in the art (see Herzenberg, et al., "Handbook of Experimental Immunology", Oxford, Blackwell, pp. 25.1-25.7; Colcher, et al., Proc. Natl. Acad. Sci. USA, **78**:3199-3203 (1981); and Muraro, et al., Intl. J. Cancer, **39**:34-44 (1987)).

The resulting hybridomas are then tested to isolate those which produce monoclonal antibodies having binding specificity to TAG-72 and human carcinomas but not to normal adult human tissues. This screening is carried out using a SPRIA as described in greater detail in the Examples provided hereinafter.

The binding affinity of monoclonal antibodies for TAG-72 is determined by means well known in the art (see Heyman, et al., J. Immunol. Methods, **68**:193-204 (1984)) and as described in detail in the Examples provided hereinafter.

The isotypes (IgG₁, IgG_{2a}, IgG_{2b}, IgG₃ or IgM) of the monoclonal antibodies are determined by means well known in the art (see Colcher, et al., Cancer Res., **41**:1451-1459 (1981)) and as described in detail in the Examples provided hereinafter.

In the non-limiting Examples provided hereinafter, in excess of four thousand hybridomas were produced by fusing (i) spleen cells of mice immunized with purified TAG-72 which was obtained from a LS-174T human colon carcinoma xenograft, and (ii) the well known and readily available NS-1 mouse myeloma line (ATCC No. TIB-18). From these hybridomas, 44 double cloned hybridomas (29 CC second generation monoclonal antibodies and 15 MATAG second generation monoclonal antibodies) were selected and characterized as described in the Examples provided hereinafter.

The CC monoclonal antibodies of the present invention are fragmented to obtain highly immunoreactive F(ab')₂ and F(ab) fragments using the enzyme pepsin by methods well known in the art (see Colcher, et al., Cancer Res., **43**: 736-742 (1983)) and as described in greater detail in the Examples provided hereinafter. The immunoreactivity of the resulting F(ab')₂, F(ab') and F(ab) fragments are determined in a competition RIA or SPRIA as described above for the complete monoclonal antibody molecule.

The second generation antibodies of the present invention are also made into recombinant forms by techniques of molecular biology well known in the art (see Rice, et al., Proc. Natl. Acad. Sci. USA, **79**:7862-7865 (1982); Kurokawa, et al., Nucleic Acids Res., **11**: 3077-3085 (1983); Oi, et al., Proc. Natl. Acad. Sci. USA, **80**:825-829 (1983); Boxx, et al., Nucleic Acids Res., **12**: 3791-3806 (1984); Boulianne, et al., Nature (London), **312**:643-646 (1984); Cabilly, et al., Proc. Natl. Acad. Sci. USA, **81**:3273-3277 (1984); Kenten, et al., Proc. Natl. Acad. Sci. USA, **81**:2955-2959 (1984); Liu, et al., Proc. Natl. Acad. Sci. USA, **81**: 5369-5373 (1984); Morrison, et al., Proc. Natl. Acad. Sci. USA, **81**:6851-6855 (1984); Neuberger, et al., Nature (London), **312**:604-608 (1984); Potter, et al., Proc. Natl. Acad. Sci. USA, **81**:7161-7165 (1984); Neuberger, et al., Nature (London), **314**:268-270 (1985); Jones, et al., Nature (London), **321**:522-525 (1986); Oi, et al., BioTechniques, **4**:214-221 (1986); Sahagan, et al., J. Immunol., **137**:1066-1074 (1986); Sun, et al., Hybridoma **5** (Suppl. 1):S-17-520 (1986); and Sun, et al., Proc. Natl. Acad. Sci. USA, **84**:214-218 (1987)).

More specifically, the second generation monoclonal antibodies of the present invention are altered to a chimeric form by substituting, e.g., human constant regions (F_c domains) for mouse constant regions by recombinant DNA techniques known in the art as described in the above cited references. These F_c domains can be of various human isotypes, i.e., IgG₁, IgG₂, IgG₃, IgG₄, or IgM.

In addition, the second generation monoclonal antibodies of the present invention are altered to an affinity modified form, avidity modified form, or both, by altering binding sites or altering the hinge region using recombinant DNA techniques well known in the art as described in the above cited references.

The recombinant antibody forms are also fragmented to produce immunoreactive fragments F(ab')₂, F(ab'), or F(ab) in the same manner as described above in which the second generation monoclonal antibodies of the present invention are fragmented.

Accordingly, as used herein, the expression "recombinant antibodies" collectively includes chimeric/ recombinant forms of the second generation monoclonal antibody of the present invention wherein the F_c domain is substituted for

an F_c domain of another species or isotype, affinity modified forms of the second generation monoclonal antibody of the present invention wherein the binding sites are altered, avidity modified forms of the second generation monoclonal antibody of the present invention wherein the hinge regions are altered, immunoreactive fragments thereof and combinations thereof.

The second generation monoclonal antibodies of the present invention are produced in large quantities by injecting a hybridoma producing a second generation monoclonal antibody of the present invention into the peritoneal cavity of pristane-primed mice, and after an appropriate time (about 1-2 weeks), harvesting ascites fluid from the mice, which yields a very high titer of homogenous monoclonal antibody, and isolating the monoclonal antibodies therefrom by methods well known in the art (see Stramignoni, et al., *Intl. J. Cancer*, **31**: 543-552 (1983)). Alternatively, the second generation monoclonal antibodies are produced by culturing a hybridoma producing a second generation monoclonal antibody of the present invention *in vitro* and isolating secreted monoclonal antibodies from the cell culture medium by methods well known in the art (see Colcher, et al., *Proc. Natl. Acad. Sci. USA*, **78**:3199-3203 (1981)).

The CC and MATAG monoclonal antibodies of the present invention are thus produced according to the above method. The binding specificity and binding affinity of these monoclonal antibodies and a comparison of such with B72.3 are discussed in greater detail in the Examples provided hereinafter.

III. Uses of the Monoclonal Antibodies

The second generation monoclonal antibodies of the present invention, immunoreactive fragments or recombinants thereof, can be used either alone, in combination with one another, or in combination with other antibodies, such as B72.3 or immunoreactive fragments thereof, in: (1) *in vitro* diagnostic assays using labelled monoclonal antibodies for the detection of TAG-72 in body fluids of patients; (2) *in vivo* diagnostic assays (diagnostic imaging) using the second generation monoclonal antibodies of the present invention, immunoreactive fragments or recombinants thereof, conjugated to an imaging marker, for the *in situ* detection of carcinoma lesions; (3) *in vivo* cancer treatment using the second generation monoclonal antibodies of the present invention, immunoreactive fragments or recombinants thereof alone or conjugated to a therapeutic agent such as radionuclide, drug, toxin, effector cells, other antibodies or via a complement mechanism; (4) immunohistopathology or immunocytochemistry for the detection or phenotyping of carcinoma cells; and (5) as immunogens to activate the anti-idiotypic network for active immunotherapy against carcinomas.

A. In Vitro Diagnostic Assays

In vitro diagnostic assays of human carcinomas or metastases thereof by detecting TAG-72 in body fluids of patients using the second generation monoclonal antibodies of the present invention, immunoreactive fragments or recombinants thereof are described in greater detail below.

The body fluid obtained from a patient is contacted with the monoclonal antibody of the present invention, immunoreactive fragment or recombinant thereof. A diagnosis is then made by determining the amount of monoclonal antibody, immunoreactive fragment or recombinant thereof binding to substances (TAG-72) present in the body fluid and comparing the amount of monoclonal antibody, immunoreactive fragments or recombinants thereof bound to the body fluid substances to a predetermined base level as hereinafter defined. The amount of bound monoclonal antibody, immunoreactive fragment or recombinant thereof exceeding the base level indicates the presence of a human carcinoma or metastases thereof.

Examples of body fluids which can be used in the *in vitro* method are any body fluids suspected of containing TAG-72. Preferred examples thereof include blood (serum or plasma), sputum, nipple discharge, cyst fluid, ascites fluids, pleural effusions, seminal plasma, semen, urine and prostatic fluid and/or biopsy specimens. Serum or plasma are the most preferred body fluids employed in the present invention. The body fluids can be obtained by methods readily known to or determined by those skilled in the art.

The body fluid is contacted with the second generation monoclonal antibody of the present invention, immunoreactive fragment or recombinant thereof and the amount of monoclonal antibody, immunoreactive fragment or recombinant thereof bound to substances in the body fluid is determined by means of immunochemical assays well known to those skilled in the art, as described, for example, in Klug, et al., *Cancer Res.*, **44**:1048-1053 (1984); Klug, et al., *Intl. J. Cancer*, **38**:661-669 (1986); Herlyn, et al., *J. Clin. Immunol.*, **2**:135-140 (1982); Metzgar, et al., *Proc. Natl. Acad. Sci. USA*, **81**:5242-5246 (1984); Papsidero, et al., *Cancer Res.*, **44**:4653-4657 (1984); Hayes, et al., *J. Clin. Invest.*, **75**:1671-1678 (1985); Killian, et al., *Cancer Res.*, **45**:886-891 (1985); Hedin, et al., *Proc. Natl. Acad. Sci. USA*, **80**:3470-3474 (1983); Pekary, et al., *Clin. Chem.*, **30**:1213-1215 (1984); Bast, et al., *New England J. Med.*, **309**:883-887 (1983); and Bellet, et al., *Proc. Natl. Acad. Sci. USA*, **81**: 3869-3873 (1984).

An example of one type of immunochemical assay useful in the present invention is a sandwich immunoradiometric assay (hereinafter "IRMA"). In this type of assay, the presence of antigen (TAG-72) is measured directly by reacting it

with an excess of labelled monoclonal antibody. In such an assay, before the antigen is reacted with the labelled monoclonal antibody, the antigen is insolubilized on an immunoadsorbent which specifically binds the antigen. The immunoadsorbent is formed by affixing a second generation monoclonal antibody, immunoreactive fragment or recombinant thereof to a substrate such as an immunobead. In sandwich assays for an antigen which is monomeric, two antibodies which recognize distinct epitopes on the antigen are required, i.e., a so-called "double determinant" assay, so that there is no competition for binding to the antigen. In sandwich assays, one antibody is bound to the immunoadsorbent and the other antibody is used as the labelled tracer. In assays for dimeric or polymeric antigens, the same antibody can be bound to the immunoadsorbent as the labelled tracer.

Sandwich IFMAs may be performed in a forward, reverse or simultaneous mode.

In a forward sandwich assay for TAG-72, a monoclonal antibody is affixed to a solid phase such as an immunobead to form an immunoadsorbent specific for TAG-72. A body liquid sample containing TAG-72 is then incubated with the immunoadsorbent. Incubation is maintained for a sufficient period of time to allow TAG-72 in the body fluid to bind to the immobilized monoclonal antibody on the immunoadsorbent. After this first incubation, the solid phase immunoadsorbent is separated from the incubation mixture. The immunoadsorbent may be washed to remove unbound interfering substances, such as non-specific binding proteins, which may also be present in the body fluid. The immunoadsorbent containing TAG-72 bound to an immobilized monoclonal antibody is subsequently incubated with a labelled monoclonal antibody, immunoreactive fragment or recombinant thereof. Again, the incubation is carried out for a period of time and under conditions sufficient to ensure binding of the labelled monoclonal antibody, immunoreactive fragment or recombinant thereof to TAG-72. After the second incubation, another wash may be performed to remove unbound labelled monoclonal antibody, immunoreactive fragment or recombinant thereof from the solid phase immunoadsorbent. The labelled monoclonal antibody, immunoreactive fragment or recombinant thereof bound to the solid phase immunoadsorbent is then measured, and the amount of labelled monoclonal antibody, immunoreactive fragment or recombinant thereof detected serves as a direct measure of the amount of TAG-72 present in the body fluid.

The sandwich IFMA may also be performed in reverse and simultaneous modes. In the reverse mode, an incubation mixture is formed of the body fluid to be tested and soluble labelled monoclonal antibody, immunoreactive fragment or recombinant thereof directed against TAG-72. The mixture is incubated, then contacted with a solid phase immunoadsorbent also containing a monoclonal antibody, immunoreactive fragment or recombinant thereof directed against TAG-72. After another incubation, the immunoadsorbent is separated from the mixture and the label bound to the immunoadsorbent is taken as an indication of the amount of TAG-72 in the body fluid.

In the simultaneous mode, an incubation mixture is formed of the body fluid, the labelled monoclonal antibody, immunoreactive fragment or recombinant thereof and the solid phase immunoadsorbent. After incubation for a sufficient time, the solid phase immunoadsorbent is separated from the mixture and the label associated with the immunoadsorbent is measured to give an indication of the amount of TAG-72 in the body fluid.

For each incubation step in the various assay modes described above, the time and conditions of incubation are selected to ensure maximum binding of TAG-72 to the immobilized monoclonal antibody, immunoreactive fragment or recombinant thereof and to labelled monoclonal antibody, immunoreactive fragment or recombinant thereof, out generally are about 6 to 16 hours at room temperature (22° to 27°C).

In addition to the IFMA's described above, other immunoassays useful in the present invention include competitive binding assays such as RIAs and fluorescent or enzymelinked immunoassays (hereinafter "ELISAs"). On suitable type of RIA is a SPRIA.

For a SPRIA, a solid phase immunoadsorbent is prepared as described for the IFMA. The immunoadsorbent is then incubated with the body fluid and a known amount of labelled TAG-72 for a period of time and under conditions which permit binding of TAG-72 to the immunoadsorbent. The immunoadsorbent is separated from the body fluid and the amount of label associated therewith is assessed. By reference to a preestablished inhibition curve defining the relationship between labelled TAG-72 associated with the immunoadsorbent, the amount of unlabelled human TAG-72 in the body fluid is determined.

In the various SPRIAs, the immunoadsorbent is separated from incubation mixtures containing the body fluid, the labelled antibody or both. Separation can be accomplished by any conventional separation technique such as sedimentation or centrifugation. Preferably, though not necessarily, the immunoadsorbent is washed prior to contacting it, when required, with a second incubation medium and prior to measuring the amount of label associated with the immunoadsorbent. The washing removes non-specific interfering substances or excess labelled antibody which may affect the accuracy and sensitivity of the assay.

The particular label employed to label the second generation monoclonal antibodies of the present invention, immunoreactive fragments or recombinants thereof or TAG-72 in the above-described assays is not critical to the present invention and can be a radioisotope such as ^{32}P , ^{14}C , ^3H , ^{125}I , ^{131}I , or ^{35}S for the IFMA and RIA or a fluorescent molecule such as fluorescein or rhodamine or an enzyme, which, under the presence of an appropriate substrate converts the substrate to a color product for the ELISA. Examples of such enzymes include alkaline phosphatase and horseradish peroxidase.

As the last step in the in vitro diagnostic method according to the present invention, the amount of second generation monoclonal antibody, immunoreactive fragment or recombinant thereof, binding to substances (TAG-72) present in the body fluid is compared to a predetermined base level.

The determination of the base level of monoclonal antibody assay binding to be expected is a determination routinely made by those of ordinary skill in the art when defining the parameters necessary for the reading of a diagnostic test of this sort. These determinations may be made without undue experimentation, particularly in light of the teachings set forth herein.

Generally, the "base level" is defined as (1) two standard deviations above the mean of the normal population, or (2) the level below which 99% of the normal population falls.

B. In Vivo Diagnostic Assays

In vivo diagnostic assay of human carcinomas or metastases thereof using the second generation monoclonal antibodies of the present invention, immunoreactive fragments or recombinants thereof, are described in more detail below.

A second generation monoclonal antibody of the present invention, immunoreactive fragment or recombinant thereof, conjugated to an imaging marker is administered to a patient (or subsequently administering the marker or linker conjugate marker after administration of the second generation monoclonal antibody) and then the presence of the imaging marker in the patient is detected by exposing the patient to an appropriate means for detecting the marker.

Administration and detection of the antibody-imaging marker conjugate as well as a methods of conjugation of the antibody to the imaging marker are accomplished by methods readily known to or readily determined by those skilled in the art, as described, for example, in Goldenberg, et al., New England J. Med., 298: 1384-1388 (1978); Goldenberg, et al., J.A.M.A., 250:630-635 (1983); Goldenberg, et al., Gastroenterol., 84:524-532 (1983); Siccaldi, et al., Cancer Res., 45:4817-4822 (1986); Epenetos, et al., Cancer, 55:984-987 (1985); Philben, et al., Cancer, 57:571-576 (1986); Chiou, et al., Cancer Res., 45:6140-6146 (1985); Hwang, et al., J. Natl. Cancer Inst., 76:849-855 (1986); Colcher, et al., Cancer Res., 43:736-742 (1983); Colcher, et al., "Laboratory Research Methods in Biology and Medicine Immunodiagnosics", New York, Alan R. Liss, pp. 215-258 (1983); Keenan, et al., J. Nucl. Med., 25:1197-1203 (1984); Colcher, et al., Cancer Res., 43:1185-1189 (1987); Esteban, et al., Intl. J. Cancer, 39:50-59 (1987); Martin, et al., Curr. Surg., 41:193-194 (1984); Martin, et al., Hybridoma, 5:S97-S108 (1986); and Martin, et al., Am. J. Surg., 150:672-675 (1985).

The dosage will vary depending upon the age and weight of the patient, but generally a one time dosage of about 0.1 to 20 mg of antibody-marker conjugate per patient is sufficient. A more preferred dosage is about 1.0 to 2.0 mg of antibody-marker conjugate per patient.

Examples of imaging markers which can be conjugated to the antibody are well known to those skilled in the art and include substances which can be detected by diagnostic imaging using a gamma scanner or hand held gamma probe or Positron Emission Tomography or the like as described by the references cited above and substances which can be detected by nuclear magnetic resonance imaging using a nuclear magnetic resonance spectrometer or the like as described in the references cited above.

Suitable examples of substances which can be detected using a gamma scanner or the like include ^{125}I , ^{131}I , ^{123}I , ^{111}In , and $^{99\text{m}}\text{Tc}$. ^{111}Tl and $^{99\text{m}}\text{Tc}$ are preferred due to their low energy and suitability for long range detection.

An example of a substance which can be detected using a nuclear magnetic resonance spectrometer or the like is the nuclear magnetic spin-resonance isotope gadolinium (Gd).

C. In Vivo Treatment

In vivo treatment of human carcinomas or metastases thereof using second generation monoclonal antibodies of the present invention, immunoreactive fragments or recombinants thereof is described in greater detail below.

A pharmaceutically effective amount of a second generation monoclonal antibody of the present invention, immunoreactive fragment or recombinant thereof unconjugated or conjugated to a therapeutic agent is administered to a patient.

Methods of preparing and administering the monoclonal antibody-therapeutic agent conjugate as well as suitable dosages will depend on the age and weight of the patient and the therapeutic agent employed and are well known to or readily determined by those skilled in the art. Representative protocols are described in the references cited below.

Examples of the monoclonal antibody-therapeutic agent conjugates which can be used in therapy include antibodies coupled to radionuclides, such as ^{131}I , ^{90}Y , ^{105}Rh , ^{47}Sc , ^{67}Cu , ^{212}Bi , and ^{211}At , as described, for example in Goldenberg, et al., Cancer Res., 41:4354-4360 (1981); Carrasquillo, et al., Cancer Treat. Rep., 68:317-328 (1984); Zelcberg, et al., J. Natl. Cancer Inst., 72:697-704 (1984); Jones, et al., Intl. J. Cancer, 35:715-720 (1985); Lange, et al., Surgery,

98:143-150 (1985); Kaltovich, et al., J. Nucl. Med., 27:897 (1986); Order, et al., Intl. J. Radiother. Oncol. Biol. Phys., 8: 259-261 (1982); Courtenay-Luck, et al., Lancet, 1:1441-1443 (1983); and Ettinger, et al., Cancer Treat. Rep., 66: 289-297 (1982); antibodies coupled to other drugs or biological response modifiers such as methotrexate, adriamycin, and interferon as described, for example in Chabner, et al., "Cancer, Principles and Practice of Oncology", Philadelphia, PA, J.B. Lippincott Co., Vol. 1, pp. 290-328 (1985); Oldham, et al., "Cancer, Principles and Practice of Oncology", Philadelphia, PA, J.B. Lippincott Co., Vol. 2, pp. 2223-2245 (1985); Deguchi, et al., Cancer Res., 46:3751-3755 (1986); Deguchi, et al., Fed. Proc., 44:1684 (1985); Embleton, et al., Br. J. Cancer, 49:559-565 (1984); and Pimm, et al., Cancer Immunol. Immunother., 12:125-134 (1982); antibodies coupled to toxins, as described, for example, in Uhr, et al., "Monoclonal Antibodies and Cancer", Academic Press, Inc., pp. 85-98 (1983); Vitetta, et al., "Biotechnology and Bio. Frontiers", Ed. P.H. Abelson, pp. 73-85 (1984); and Vitetta, et al., Sci., 219:644-6540 (1983), the disclosures of all of which are specifically incorporated herein by reference; heterobifunctional antibodies for example, antibodies coupled or combined with another antibody so that the complex binds both to the carcinoma and effector cells, e.g., killer cells, such as T cells, as described, for example, in Perez, et al., J. Exper. Med., 163:166-178 (1986); and Lau, et al., Proc. Natl. Acad. Sci. USA, 82:8648-8652 (1985); and native, i.e., non-conjugated or non-complexed, antibody, as described in, for example, Herlyn, et al., Proc. Natl. Acad. Sci. USA, 79:4761-4765 (1982); Schulz, et al., Proc. Natl. Acad. Sci. USA, 80:5407-5411 (1983); Capone, et al., Proc. Natl. Acad. Sci. USA, 80:7328-7332 (1983); Sears, et al., Cancer Res., 45:5910-5913 (1985); Nepom, et al., Proc. Natl. Acad. Sci. USA, 81:2864-2867 (1984); Koprowski, et al., Proc. Natl. Acad. Sci. USA, 81:216-219 (1984); and Houghton, et al., Proc. Natl. Acad. Sci. USA, 82:1242-1246 (1985).

In this method, the monoclonal antibody-therapeutic agent conjugate can be delivered to the carcinoma site thereby directly exposing the carcinoma tissue to the therapeutic agent.

D. Immunohistochemistry and Immunocytochemistry Assays

Immunohistochemistry (hereinafter "IHC") and immunocytochemistry (hereinafter "ICC") assays for the diagnosis of human carcinomas or metastases thereof or to make differential diagnoses using the second generation monoclonal antibodies of the present invention, are carried out as described in detail below.

A second generation monoclonal antibody of the present invention, is added to a slide containing a 5 μ section of a biopsy specimen (for IHC) or cells (for ICC) from body fluid (such as pleural effusion, ascites, sputum, or vaginal fluid). A series of linkers (e.g., biotinylated horse anti-mouse IgG followed by avidin DH:biotinylated horseradish peroxidase complex) and dyes (e.g., diaminobenzidine) are then added to the slides to detect binding of the second generation monoclonal antibody, immunoreactive fragment or recombinant thereof to carcinoma cells in the biopsy or body fluid by a color reaction, i.e., carcinoma cells will look reddish-brown while normal and benign cells will look blue (the background stain). Alternate linkers, dyes and subsequent color reactions, may of course be applied (see Sternberger, "Immunocytochemistry", New York, John Wiley & Sons, Second Edition, pp. 82-169 (1979)). By this method: (a) carcinoma cells can be detected in biopsy specimens and body fluids as an adjunct to making a diagnosis of cancer, and (b) a differential diagnosis can be made; for example, TAG-72 has been shown to be present in adenocarcinoma of the lung and adenosquamous carcinoma of the lung but not in small cell carcinoma. Thus, detection of binding of the second generation monoclonal antibody of the present invention, immunoreactive fragment or recombinant thereof to a lung biopsy would rule out small cell lung cancer. Furthermore, since TAG-72 has been shown not to be expressed in malignant mesothelioma, the second generation monoclonal antibody of the present invention, therefore can be used to differentiate adenocarcinoma of the lung from malignant mesothelioma.

The use of IHC and ICC assays for the diagnosis of cancer or to make differential diagnoses are accomplished by methods known or readily determined by those skilled in the art, as described, for example, in Nuti, et al., Intl. J. Cancer, 29:539-545 (1982); Stramignoni, et al., Intl. J. Cancer, 31:543-552 (1983); Szpak, et al., Acta Cytologica, 28: 356-367 (1984); Johnston, et al., Cancer Res., 45:1894-1900 (1985); Szpak, et al., Am. J. Path., 122:252-260 (1986); Martin, et al., Am. J. Clin. Path., 86:10-18 (1986); Nuti, et al., Intl. J. Cancer, 37:493-498 (1986); Johnston, et al., Cancer Res., 46:850-857 (1986); Thor, et al., Cancer Res., 46:3118-3124 (1986); Ohuchi, et al., Intl. J. Cancer, 38:643-650 (1986); Johnston, et al., Cancer Res., 45:6462-6470 (1986); and Thor, et al., Cancer Res., 47:505-512 (1987).

The amount of second generation monoclonal antibody of the present invention, used per slide and the incubation time and temperature may vary, but generally, the IHC and ICC assays are conducted at about 4°C for about 18 hours using about 40 μ g per ml of monoclonal antibody.

E. Activating the Anti-Idiotypic Network

Activating the anti-idiotypic network for cancer therapy using the second generation monoclonal antibodies of the present invention, immunoreactive fragments or recombinants thereof is carried out as described in detail below.

A second generation monoclonal antibody of the present invention, immunoreactive fragment or recombinant thereof (designated Ab 1) is administered to a patient at multiple intervals. The immune system of the patient will respond

by the generation of antibodies (designated Ab 2) which having binding specificity to the binding site of Ab 1. These anti-idiotypic antibodies (Ab 2's) will then elicit the formation of antibodies (designated Ab 3) which have binding specificity to the binding site of Ab 2. The Ab 2 antibodies will be an internal image of the original TAG-72, and thus the Ab 3 antibodies will have binding specificity and potentially destroy a carcinoma producing TAG-72.

The use of monoclonal antibodies to activate the idiotypic network and the procedures used to accomplish this are readily known or readily determined by those skilled in the art, as described, for example, in Nisonoff, et al., *Clin. Immunol. and Path.*, 21:397-406 (1981), Forstrom, et al., *Nature*, 303:627-629 (1983); Kauffman, et al., *J. Immunol.*, 131:2539-2541 (1983); Reagen, et al., *J. Virol.*, 48:660-666 (1983); Koprowski, et al., *Proc. Natl. Acad. Sci. USA*, 81:216-219 (1984), Herlyn, et al., *J. Immunol.*, 143:1300-1304 (1985); Koprowski, et al., *J. Immunol. Metho.*, 85:27-38 (1985), Koprowski, et al., *Science*, 232:100-102 (1985); Greene, et al., *J. Immunol.*, 137:2930-2936 (1986), Kohler, et al., *J. Immunol.*, 137:1743-1749 (1986), Notkins, et al., *J. Exp. Med.*, 163:1355-1360 (1986).

The activation of the anti-idiotypic network can be used to stimulate a patient's immune system so that the patient can mount an active immune response against carcinomas producing TAG-72.

The following examples are provided for illustrative purposes only and are in no way intended to limit the scope of the present invention.

Example 1

Preparation of Monoclonal Antibodies

A. Preparation of Immunogen

LS-174T colon carcinoma cells (ATCC No. CRL-188) were grown in Eagle's minimum essential medium with non-essential amino acids supplemented with 10% (v/v) heat-inactivated fetal calf serum, 100 units/ml penicillin and 100 µg/ml streptomycin. The LS-174T cells were tested for the presence of *Mycoplasma* species and were found to be negative.

Four-week old female athymic mice were inoculated subcutaneously with 1×10^6 LS-174T cells in 0.1 ml of culture medium. Carcinoma xenografts were harvested when they reached approximately 1.0 cm in diameter (15-20 days after cell implantation), quick frozen in liquid nitrogen and stored at -70°C. Large carcinoma xenografts were not used due to necrosis.

Thereafter, approximately 3 grams of frozen LS-174T human carcinoma xenograft was homogenized with an Omni Mixer for 45 sec in buffer comprising 20 mM Tris (pH 7.2) and 150 mM NaCl (hereinafter "TBS"). The homogenized xenograft was then filtered through glass wool and loaded onto a Sepharose CL-4B column sizing column (Pharmacia, Upsala, Sweden) (5.5 x 25 cm) which was previously equilibrated in TBS. The column was eluted using TBS (pH 7.2).

7.0 ml fractions were collected and examined in a direct binding assay 1/10 volume dilutions. More specifically, 50 µl of the dilutions were added to wells of a 96-well polyvinyl chloride microtiter plate (Dynatech Laboratories, Inc., Alexandria VA). To minimize nonspecific protein adsorption, the microtiter wells were treated with 100 µl of 5.0% bovine serum albumin (hereinafter "BSA") in phosphate buffered saline, comprising 8.0 mM Na₂HPO₄, 2.5 mM KCl, 140 mM NaCl, 0.5 mM MgCl₂, 1.0 mM CaCl₂, (pH 7.2) (hereinafter "PBS") and incubated for 1 hour at 37°C. Next, the BSA was removed and ¹²⁵I-B72.3, prepared as described in Colcher, et al., *Cancer Res.*, 44:5744-5751 (1984) at 50,000 cpm/25 µl per well, was added to each well. Following an overnight incubation at 4°C, unbound ¹²⁵I-B72.3 was removed by washing with 1.0% BSA (v/v) in PBS. The bound ¹²⁵I-B72.3 was detected by cutting individual wells from the plate and measuring the radioactivity in a gamma counter (RIAgamma, LKB, Bromma, Sweden).

Thereafter, the peak fractions were pooled (130 mls of material), and loaded onto a B72.3 affinity column which was washed with TBS. The B72.3 affinity column was prepared as described in Johnson, et al., *Cancer Res.*, 46:850-857 (1986) and comprised 100 ml of 1,1'-carbonyldiimidazole activated affinity matrix Reacta-Gel HW65F (Pierce, Rockford, IL) coupled with 200 mg of B72.3. The column was washed with TBS and the bound protein was eluted with 3.0 M NaI in TBS. The column was finally washed with TBS.

5.0 ml fractions were collected and examined in a second direct binding assay carried out as described above. The peak fractions were pooled (92 mls of protein) dialyzed against 4.0 liters of 20 mM Tris (pH 7.2) at 4°C overnight. The purified TAG-72 thus obtained was concentrated in Aquacide II, sodium salt of carboxymethyl cellulose (Calbiochem, San Diego, CA) and used as the immunogen.

B. Immunizations

1. CC Group

For the group designated CC hereinafter, the four-week old BALB/c mice were immunized by intraperitoneal

inoculation of 10 µg of TAG-72 purified as described above which had been pre-mixed with an equal volume of complete Freund's adjuvant. After 80 days, the mice received booster doses intraperitoneally of 50 µg of TAG-72 purified as described above which had been pre-mixed with an equal volume of incomplete Freund's adjuvant. Seven days later the mice received 10 µg of TAG-72 in saline, by intravenous inoculation. Spleens were harvested three days later for cell infusion.

2. MATAG Group

For the group designated MATAG hereinafter, two four-week old BALB/c mice were immunized by intraperitoneal inoculation of 50 µg of TAG-72 purified as described above which had been pre-mixed with an equal volume of complete Freund's adjuvant. After seven days, the mice received booster doses intraperitoneally of 50 µg of TAG-72 purified as described above which had been pre-mixed with an equal volume of incomplete Freund's adjuvant. Seven days later the mice received 10 µg of TAG-72 in saline, by intravenous inoculation. Spleens were harvested three days later for cell fusion.

C. Preparation of Hybridomas

Somatic cell hybrids (hybridomas) were prepared using a modification of the method of Herzenberg, et al., "Handbook of Experimental Immunology", Oxford, Blackwell, pp. 25.1-25.7 (1978). More specifically, single cell suspensions of spleen cells from the immunized mice were made by passing the spleen tissue of the mice through a No. 3 mesh stainless steel screen (B. Fenenco Co., Inc., Norcester, MA). The spleen cells and NS-1 mouse myeloma cells (ATCC No. TIB-18) were washed in RPMI-1640 medium, containing 2.0 mM glutamine, 1.0 mM sodium pyruvate, 50 units/ml penicillin, 50 µg/ml streptomycin and 0.25 µg/ml Fungizone, an antimycotic mixture (Grand Island Biological Company, Grand Island, NY). Then, the spleen cells and NS-1 mouse myeloma cells were mixed at a 4:1 ratio, and fused with 50% (v/v) polyethylene glycol (M.W. 1500) (BDH Chemical Ltd., Poole, England). After fusion, individual wells of 96-well microtiter plates (Costar, Cambridge, MA) were seeded with 1×10^6 total cells (0.1 ml) of the cell suspension. Fused cells were then selected for growth with HAT media.

Cloning of hybridoma cell lines was performed by limiting dilution. Specifically, twenty-four wells of a 96-well microtiter plate (Costar, Cambridge, MA) were seeded with one of the following concentrations of hybridoma cells: 10 cells/well, 5 cells/well, 1.0 cell/well, or 0.5 cell/well. Mouse thymocytes, derived from the thymus glands of four-week old BALB/c mice, were added to each well as feeder cells at a concentration of 10^6 cells/well. Wells were seeded at the concentration that eventually resulted in the growth of single cell cultures.

A total of 2,567 initial hybridoma cultures were obtained for the CC group and a total of 2,000 initial hybridoma cultures were obtained for the MATAG group. All hybridoma cell lines selected for further screening were cloned twice.

D. Solid Phase Radioimmunoassays

1. CC Group

The CC group was assayed in a SPRIA using the cell extracts from a metastatic breast carcinoma and normal spleen and liver.

More specifically, 50 µl of the cell extracts (5 µg) were added to each well of a Cooke round bottom polyvinyl chloride microtiter (Dynatech Laboratories, Alexandria, VA) plate and allowed to dry. To minimize non-specific protein adsorption, microtiter wells were treated with 100 µl of 5.0% (v/v) BSA in PBS and incubated with the sample covered for 1 hour. This and all subsequent incubations were at 37°C. The BSA was then removed and the wells were washed one time with 1.0% (v/v) BSA in PBS. Next, 50 µl of hybridoma supernatant was added per well. After a 1 hour incubation, the unbound immunoglobulin was removed by washing the plates three times with 1.0% (v/v) BSA in PBS at 100 µl/wash.

To determine antibody binding, the wells were then incubated with 25 µl of 125 I-goat-anti-mouse IgG (γ chain specific) (Kirkegaard & Perry, Gaithersburg, MD) at 75,000 cpm/25 µl per well for 1 hour at 37°C. The supernatant was aspirated and the plates were washed four times with 1.0% (v/v) BSA in PBS at 100 µl/well/wash.

The plates were then subjected to autoradiography using Kodak XAR film and Dupont Lightning-Plus intensifying screens. The films were developed after 16 hours at -70°C. The bound cpm were also detected by cutting the individual wells from the plate and measuring the cpm in a gamma counter.

The results yielded 433 CC cultures which had binding specificity in the SPRIA, to the carcinoma extract but not to the normal extracts.

All of these 433 CC cultures were then assayed, in a SPRIA as described above, using the cell extracts shown in Table I below.

TABLE I

Primary colon carcinoma
Metastatic breast carcinoma
Normal kidney
Normal liver
Normal colon
Normal stomach
Normal bone marrow
Normal lung
Normal thyroid
Polymorphonuclear leukocyte
Red blood cell

The results yielded 99 CC cultures which had binding specificity, in the SPRIA, to the carcinoma extracts but not to the normal extracts listed in Table I above.

Next, all of the 99 cultures were cloned into 9,504 wells and each well was checked for growth of a single colony. Those with a single colony were selected for further assay. Those that were selected were assayed, in a SPRIA as described above, using extracts of a human breast carcinoma and primary colon carcinoma as well as normal liver. The colonies that had binding specificity, in the SPRIA, to the carcinoma extracts but not to normal liver extract were recloned and again assayed for binding specificity, in the SPRIA, to the colon carcinoma extract but not to the normal liver extract. This resulted in the generation of 29 CC monoclonal antibodies which had binding specificity to the colon carcinoma but not the normal liver extracts (see Figure 1).

All of the 29 CC monoclonal antibodies shown in Figure 1 exhibit binding specificity to extracts of colon adenocarcinoma, but lack binding specificity to extracts of the following normal and/or benign tissues: colon (minimal binding specificity to superficial goblet cells), ovary, stomach (minimal binding specificity to goblet cells of intestinal metaplasia), endocervix (minimal binding specificity to glandular epithelium), brain, kidney, spleen, lung (minimal binding specificity to epithelium), skin (minimal binding specificity to sebaceous glandular epithelium), liver, prostate, uterus (binding specificity to secretory phase endometrium only), adrenal, pancreas, heart, lymph node, bone marrow, breast and small intestine (minimal binding specificity to superficial mucosal cells).

Of the 29 CC monoclonal antibodies so produced, the hybridomas producing preferred monoclonal antibodies have been deposited at the American Type Culture Collection under CC 49 (ATCC No. HB-9459); CC 83 (ATCC No. HB-9459); CC 46 (ATCC No. HB-9458); CC 92 (ATCC No. HB-9454); CC 30 (ATCC No. HB-9457); CC 11 (ATCC No. HB-9455); and CC 15 (ATCC No. HB-9460).

2. MATAG Group

The MATAG group was assayed in a SPRIA essentially as described above for the CC group using a 1/80 dilution per well of TAG-72 in PBS except that to detect binding of antibody, 50 µl of rabbit-anti-mouse IgM (Cooper Biomedical, Malvern, PA) was added to each well. The plates were incubated for 1 hour at 37°C, after which time ¹²⁵I-labelled Protein A (SPA) (Pharmacia, Upsala, Sweden) at 50,000 cpm/25 µl was added per well and again allowed to incubate at 37°C for 1 hour. The unbound SPA was removed by extensive washing with 1.0% (v/v) BSA in PBS.

Of the 2000 MATAG cultures assayed using TAG-72 and PBS, 110 were found to have binding specificity to TAG-72. Further cloning and assaying in a SPRIA as described above, using TAG-72 yielded 34 cultures which had binding specificity with colon cancer extract and TAG-72 but not a normal liver extract. These were cloned into 3,264 wells and approximately 20 wells of each of the original 34 cultures were assayed, in a SPRIA as described above, using TAG-72 and PBS. This yielded 23 cultures which had binding specificity to TAG-72. The 23 cultures were subsequently grown up and further assayed, in a SPRIA as described above, for lack of binding specificity to normal spleen and normal liver and binding specificity to a metastatic breast carcinoma extract, as well as being assayed, in a SPRIA as described above, using TAG-72 and PBS. The results yielded 15 cultures which exhibited binding specificity to the carcinoma extract and TAG-72 but not to the normal extracts. These cultures were then recloned and reassayed, in a SPRIA as described above, to produce 15 MATAG monoclonal antibodies (see Figure 1).

All of the MATAG monoclonal antibodies shown in Figure 1 exhibit binding specificity to extracts of ovarian carcinoma, colon adenocarcinoma, infiltrating ductal carcinoma of the breast, non-small cell lung carcinoma, but lack binding specificity to extracts of the following normal and/or benign tissues: colon (minimal binding specificity to mucosal goblet cells), ovary, benign effusions (minimal binding specificity to lymphocytes and mesothelial cells), lung (minimal binding

specificity to bronchial epithelium), spleen, liver, breast, kidney, bone marrow, stomach (minimal binding specificity to superficial epithelium), skin, nerve, parathyroid, heart, pancreas, lymph node, adrenal, thyroid, small intestine (minimal binding specificity to superficial mucosa), brain, gall bladder, cervix, uterus (binding specificity to secretory phase of endometrium only), endocervix (minimal binding specificity to endocervical glandular epithelium), bladder, appendix, fallopian tube, muscle, salivary gland, thymus, testis, and esophagus.

Of the 15 MATAG monoclonal antibodies so produced, the hybridoma producing MATAG 12 is preferred and has been deposited at the American Type Culture Collection under MATAG 12 (ATCC No. HB-9456).

Example 2

Isotyping Assay

1. CC Group

For the CC group, 50 μ l of polyclonal anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) was absorbed onto a 96-well polyvinyl chloride (Dynatech Laboratories, Alexandria, VA) microtiter plate. The IgG was diluted with PBS. The plates were incubated overnight at 37°C. The following day, 100 μ l of 5.0% (w/v) BSA in PBS was added to each well and allowed to incubate for 1 hour to minimize non-specific absorption. The wells were then washed with 1.0% (w/v) BSA in PBS. 5 μ l of undiluted CC culture supernatant was added to each of two wells. The plates were again incubated for 1 hour at 37°C after which time they were washed 3 times with 1.0% (w/v) BSA in PBS. Rabbit-anti-mouse IgG₁, IgG_{2b}, IgG₃, IgM, IgA (Cooper Biomedical, Malvern, PA) DC-12 (NIH, NCI, LTIB) and control 1.0% (w/v) BSA in PBS were added at 50 μ l per well. Following a 1 hour incubation, the plates were washed 3 times as described above. Then 50,000 cpm of ¹²⁵I-labelled Protein A (SPA) were added to each well, incubated for 1 hour, washed 4 times with 1.0% (w/v) BSA in PBS and the cpm per well was counted in a gamma counter. The results are shown in Figure 1.

2. MATAG Group

For the MATAG group, isotypes were determined by parallel assays essentially as described above for the CC group. However, for detection, one assay used ¹²⁵I-labelled goat-anti-mouse IgG (Kirkegaard & Perry, Gaithersburg, MD) and the other assay used ¹²⁵I-labelled goat-anti-mouse IgM (Kirkegaard & Perry, Gaithersburg, MD) in place of ¹²⁵I-labelled Protein A (SPA).

The MATAG group was further characterized by High Performance Liquid Chromatography (hereinafter "HPLC") analysis for their pentameric structure. HPLC analysis was performed using a Zorbax GF-450 column, 0.94 x 25 cm (Dupont, Wilmington, DE), equilibrated in 0.2 M sodium phosphate (pH 6.8). 100 μ l MATAG culture supernatant was loaded on the column and the column was run at a flow rate of 0.5 ml/min, 0.5 ml fractions were collected at 1 min intervals. The fractions were analyzed for isotypes as described above. The results are shown in Figure 1.

Example 3

Competition RIA

Competition RIAs were performed to determine whether B72.3 and the CC monoclonal antibodies of the present invention recognize different antigenic determinants. More specifically, B72.3 and the CC monoclonal antibodies were assayed for their ability to compete for the binding of ¹²⁵I-labelled B72.3 to an extract of LS-174T colon carcinoma cells in the following manner.

5.0 μ g of LS-174T colon carcinoma cell extract was absorbed in each well of a polyvinyl chloride microtiter plate (Dynatech Laboratories, Alexandria, VA) and varying amounts of competing CC monoclonal antibody (from 10 μ g/ μ l to 0.004 μ g/ μ l) was added to saturate the binding sites. After incubation for 6 hours at 4°C, 50,000 cpm/25 μ l of ¹²⁵I-B72.3, was added to each well and incubated for 12 hours at 4°C. Bound ¹²⁵I-B72.3 was determined by cutting individual wells and measuring cpm in the wells in a gamma counter. The cpm in the wells pre-incubated with saturating amounts of B72.3 as a competitor was considered 100% competition. The results are shown in Figure 2A, 2C, 2E, and 2G. In Figure 2A, CC 41 was used as the competing antibody. In Figure 2C, CC 60 was used as the competing antibody. In Figure 2E, CC 83 was used as the competing antibody. In Figure 2G, CC 49 was used as the competing antibody.

As shown in Figures 2A and 2C, CC 41 and CC 60 did not compete at all with B72.3. This demonstrates that CC 41 and CC 60 having specificity for a different epitope on TAG-72 than B72.3. As shown in Figures 2E and 2G, CC 83 and CC 49 partially compete with B72.3. This demonstrates that the epitopes recognized by CC 83 and CC 49 share partial (but not complete) homology with the B72.3 epitope on the TAG-72 molecule, or that the CC 83 and CC 49

epitopes are distinct from but near the B72.3 epitope, resulting in steric hinderance.

Thereafter, competition RIAs were performed to determine whether CC 49 recognizes the same or different antigenic determinants than B72.3, CC 30, CC 46, and CC 83. More specifically, these monoclonal antibodies were assayed for their ability to compete for the binding of ^{125}I -labelled CC 49 to an extract of LS-174T colon carcinoma cells as described above. The results obtained are shown in Figure 3. Figure 3 demonstrates that (1) the epitopes on TAG-72 recognized by monoclonal antibodies CC 46 and B72.3 share little or no homology with the epitope recognized by monoclonal antibody CC 49; (2) the epitope recognized by CC 83 shares considerable homology with that recognized by CC 49 but is not identical as revealed by the displacement of the CC 83 curve; and (3) the epitope recognized by monoclonal antibody CC 30, shares partial homology to that recognized by CC 49, or is distinct from that of CC 49 but is in proximal location resulting in steric hinderance.

Example 4

Binding Affinity

The binding affinities (affinity constants) of the second generation monoclonal antibodies of the present invention to TAG-72 were determined by a SPRIA using a modification of the procedure of Heyman, et al., *J. Immunol. Methods*, 68:193-204 (1984). More specifically, 30 μl of purified TAG-72 diluted in PBS at a concentration of 280 units/ml (units determined as described in Paterson, et al., *Int. J. Cancer*, 37:659-666 (1986)) were dried in 96 well polyvinyl chloride microtiter plates (Dynatech Laboratories, Alexandria, VA). Any remaining non-specific active groups were blocked with 5.0% (v/v) BSA in PBS. Then, 20 μl of 1:1.5 serial dilutions of the purified monoclonal antibody (purified as described in Colcher, et al., *Cancer Res.*, 44:5744-5751 (1984)), shown in Table 2 below, starting at 1.0 $\mu\text{g/ml}$ were added to the wells. After incubating overnight at 4°C, the plates were washed three times with 1.0% (v/v) BSA in PBS. Next, ^{125}I -labelled goat-anti-mouse IgG (Kirkegaard & Perry, Gaithersburg, MD) at 75,000 cpm/25 μl per well was added and left to react for 1 hour at 37°C. After washing three times with 1.0% (v/v) BSA in PBS, the cpm in the individual wells were counted as described above.

In order to convert the cpm values to concentration of bound monoclonal antibody, the remaining free monoclonal antibodies in the supernatant, which had been incubated with TAG-72 but not bound thereto, were incubated on another 96 well polyvinyl chloride microtiter plate which had been precoated with 4.0 $\mu\text{g/ml}$ of sheep anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) and detected with ^{125}I -labelled goat anti-mouse IgG (Kirkegaard & Perry, Gaithersburg, MD). In this manner, the concentration at which there was no free monoclonal antibodies remaining in the supernatant was determined for each monoclonal antibody. From these data, computer curves were generated to determine the binding affinity constant of each monoclonal antibody. The results are shown in Table 2 below.

TABLE 2

Binding Affinity Constants Measured Using TAG-72	
Purified Antibody	Affinity Constant $\times 10^9 \text{M}^{-1}$
B72.3	2.54
CC 46	3.64
CC 30	8.15
CC 15	9.13
CC 29	9.49
CC 92	14.26
CC 49	20.58
CC 83	27.72

Table 2 demonstrates that the second generation monoclonal antibodies CC 46, CC 30, CC 15, CC 29, CC 92, CC 49 and CC 83 all have higher binding affinity constants than the first generation monoclonal antibody B72.3.

The CC group was assayed in a SPRIA using the cell extracts from the LS-174T cell line and a metastatic breast carcinoma. 50 μl of the cell extract (5 μg) was added to each well of a Cooke round bottom polyvinyl chloride microtiter plate (Dynatech Laboratories, Alexandria, VA) and allowed to dry. To minimize non-specific protein absorption, microtiter wells were treated with 100 μl of 5.0% (v/v) BSA in PBS and incubated covered for 1 hour. This and all subsequent incubations were at 37°C. The BSA was then removed and the wells were washed one time with 1.0% (v/v) BSA in PBS. Next, 50 μl of hybridoma supernatant and 1:5 dilutions of the supernatant fluid was added per well. After a 1 hour incubation, the unbound immunoglobulin was removed by washing the plates three times with 1.0% (v/v) BSA in PBS.

at 100 µl/well/wash.

To determine antibody binding, the wells were then incubated with 25 µl of ¹²⁵I-goat-anti-mouse IgG (gamma chain specific) (Kirkegaard & Perry, Gaithersburg, MD) at 75,000 cpm/25 µl per well for 1 hour at 37°C. The supernatant was aspirated and the plates were washed four times with 1.0% (v/v) BSA in PBS at 100 µl/well/wash. The bound cpm were detected by cutting the individual wells from the plate and measuring the CPM in a gamma counter.

As shown in Figure 2B, CC 41 reacts with the LS extract but B72.3 does not. Note, Figure 2B and Table 2 demonstrates that CC 41 has a higher binding affinity (slope of the curve) to the Br. Ca. than B72.3. Figure 2D demonstrates that although CC 60 does not have binding specificity to the LS extract like B72.3, CC 60 has a higher binding affinity (slope of the curve) to the Br. Ca. than B72.3. Figure 2F demonstrates that CC 83 and B72.3 have similar binding properties to the Br. Ca. extract but that CC 83 has high binding affinity to the LS extract while B72.3 does not. Figure 2H demonstrates that CC 49 has high binding affinity to both the LS and Br. Ca. extracts while B72.3 has essentially no binding affinity to the LS extract.

Example 5

Western Blotting

40 µg of LS-174T cell extracts or an extract of a human breast carcinoma diluted in SDS-PAGE sample buffer comprising 0.125 M Tris-HCl (pH 6.8) 4.0% (w/v) SDS, 20% (v/v) glycerol and 10% (v/v) 2-mercaptoethanol, loaded onto a 3 to 12% (v/v) linear gradient SDS-PAGE. After electrophoresis for 8 hours at 5 milliamps/gel at 9°C, the gels were treated with transfer buffer comprising 25 mM Tris-HCl (pH 8.3), 192 mM glycine, 20% (v/v) methanol with 4 M urea and 0.5% Triton-X-100 for 1 hour at room temperature. The gel was then equilibrated with transfer buffer and the proteins were transferred to nitrocellulose paper (0.45 µm pore size) at 4°C for 16 hours at 30 V. Then, the nitrocellulose paper was incubated with 5.0% (w/v) BSA with 0.05% (v/v) Tween-20 in PBS for 3 hours at room temperature and washed with 0.05% (v/v) Tween-20 in PBS. Next, 10 ml of hybridoma tissue culture supernatant of all the CC and MATAG monoclonal antibodies were added, and incubation continued for 2 hours at room temperature with gentle agitation. After washing with PBS containing 0.05% (v/v) Tween-20, the nitrocellulose paper was incubated for 1 hour at room temperature with ¹²⁵I-labelled goat-anti-mouse IgG (Kirkegaard & Perry, Gaithersburg, MD). The nitrocellulose paper was then extensively washed overnight and exposed to Kodak XAR-5 X-ray film with a DuPont Lightning Plus intensifying screen at -70°C for 2 hours. For all experiments, NS-1 tissue culture supernatant was used as a negative control.

The Western blotting analysis demonstrated the reactivity of the CC and MATAG antibodies to a diffuse band beginning at the interface of the stacking gel with the 5-12% resolving gel that penetrated the resolving gel approximately 1 cm. This diffuse band is consistent with the high molecular weight TAG-72 mucin-like molecule. The high molecular weight band was observed with all the CC and MATAG antibodies tested and detected in both the LS-174T cell line extract and the human breast carcinoma metastases extract.

Example 6

Immunoperoxidase Studies

5.0 µm sections of formalin-fixed or frozen sections of tissue on slides were used. Fixed tissues were deparaffinized in xylene and hydrated in graded H₂O/ethanol rinses. A 15 minute incubation with 0.3% (v/v) H₂O₂ in methanol was used to block any endogenous peroxidase activity. After rinsing in PBS without Ca⁺² and Mg⁺², the slides were incubated with a 1:10 (v/v) dilution of normal goat serum for the MATAG designated antibodies for 15 minutes. This incubation and all subsequent incubations were carried out at room temperature with the exception of the primary MATAG antibody which was a 16 hour incubation at 4°C. The normal blocking serum was removed and undiluted tissue culture supernatant of the monoclonal antibody was placed on the tissue sections and the slides were incubated overnight. The supernatant IgM was removed and the slides were rinsed for 15 minutes in PBS without Ca⁺² and Mg⁺². For the MATAG designated antibodies at 1:167 (v/v) dilution of biotinylated goat anti-murine IgM (Vector Laboratories, Inc.), was added to each of the tissue sections and allowed to incubate for 30 minutes. The slides were again rinsed in PBS without Ca⁺² and Mg⁺² and then incubated for 30 minutes with ABC (Vector Laboratories, Inc.) peroxidase at room temperature. After another PBS rinse, 0.06% (v/v) 3,3' diaminobenzidine (Sigma Chemical Co., St. Louis, MO) with 0.01% (v/v) H₂O₂ was added for 5 minutes. The sections were rinsed briefly in water, counterstained with hematoxylin, dehydrated in graded ethanol/H₂O rinses, cleared (eliminating residual H₂O) in xylene, mounted with Permount (histologic mounting medium, Fisher Scientific Co.) under a coverslip, and examined with a light microscope. Each section was evaluated for the presence of reddish-brown diaminobenzidine precipitate indicative of monoclonal antibody binding. The approximate percentage of positive carcinoma cells was assigned according to the number of car-

cinoma cells positive with each monoclonal antibody divided by the total number of carcinoma cells times 100. The results are shown in Table 3 below.

TABLE 3

Binding Specificity of B72.3 vs. MATAG-12 in an Immunoperoxidase Assay of Tissue Sections		
	Percent MAb Reactive Carcinoma Cells	
	B72.3	MATAG-12
Ovarian Cancer 1	6	80
Ovarian Cancer 2	5	25
Ovarian Cancer 3	10	55
Colorectal Cancer 1	10	60
Colorectal Cancer 2	40	95

As shown in Table 3, the percent carcinoma cells reactive with B72.3 is considerably lower than that for MATAG-12. This demonstrates that MATAG-12 has a higher binding specificity for the above carcinomas and thus is more useful in immunohistochemical or immunocytochemical assays, as well as in *in vivo* diagnosis and therapy of cancer.

Example 7

In Vivo Carcinoma Testing

The monoclonal antibodies shown in Table 4 below were labelled with Na¹²⁵I using Iodogen (Pierce Chemical, Rockford, IL). More specifically, 40 µg of monoclonal antibody shown in Table 4 below were adjusted 0.1 ml 0.1 M sodium phosphate buffer (pH 7.2) and then added to a 12 cm x 75 cm glass tube coated with 20 µg of Iodogen followed by addition of 0.5 mCi of Na¹²⁵I (New England Nuclear, Boston, MA). After a 2 min incubation at room temperature, the protein was removed from the insoluble Iodogen, and the unincorporated ¹²⁵I was separated from the antibody by gel filtration through a 10 ml column Sephadex G-25™ with a buffer comprising 10 mM sodium phosphate, pH 7.2. The labelled monoclonal antibody in the void was pooled and dialyzed against 10 mM sodium phosphate buffer (pH 7.2) containing 5.0 mM NaI. The iodination protocol yielded labelled IgG monoclonal antibody with a specific activity of 5.0 to 15 µCi/µg (approximately 8.0 to 25 x 10⁶ cpm/µg).

Female athymic mice (nu/nu) on a BALB/c background were obtained from Charles River, Inc., or the Frederick Cancer Research Facility at approximately 4 weeks of age. One week later, mice were inoculated subcutaneously (0.1 ml/mouse) with the LS-174T human colon carcinoma cells (1 x 10⁶ cells/animal).

Athymic mice bearing carcinomas 0.3 to 1.5 cm in diameter, approximately 2 to 3 weeks after inoculation of the cells were given injections intraperitoneally of 1.5 µCi (0.1 µg) in PBS of the monoclonal antibodies shown in Table 4 below, which had been iodinated as described above. Groups of five mice were sacrificed at varying times by exsanguination, the carcinoma and normal tissues were excised and weighed, and the cpm were measured in a gamma counter. The cpm/mg of each tissues was then determined and compared to that found in the carcinoma. The results are shown in Table 4 and Figures 4A and 4B.

TABLE 4

Percent Injected Dose Per Gram of ¹²⁵ I-Labelled Antibody*							
Tissue	B72.3	CC 11	CC 46	CC 30	CC 92	CC 83	CC 49
Carcinoma	6.6	26.6	13.2	23.1	12.4	22.9	23.4
Liver	0.8	1.2	0.5	0.8	0.8	0.7	1.2
Spleen	0.5	1.1	0.5	1.0	1.0	0.7	1.2
Kidney	0.6	1.1	0.4	1.0	1.0	0.7	0.4
Lung	1.4	2.4	1.1	2.1	2.0	1.8	0.6
Blood	2.9	6.2	2.1	4.1	3.8	4.6	1.1

*At 168 hours post monoclonal antibody administration.

As shown in Table 4, the percent of injected dose to tumor for B72.3 is considerably lower than that for the CC antibodies of the present invention. Even though monoclonal antibody CC 46 has only a slightly higher affinity constant than B72.3, Table 4 shows that CC 46 is clearly more efficient in targeting the human tumor *in situ* than is B72.3. This

demonstrates that the second generation monoclonal antibodies of the present invention are more efficient for in vivo carcinoma targeting than monoclonal antibody B72.3 and thus are more useful in in vivo diagnosis and therapy of cancer. Figures 4A and 4B show the different binding kinetics and carcinoma/normal tissue ratios at various time points for CC 11 and CC 46, respectively. Figures 4A and 4B demonstrate that these monoclonal antibodies have the ability to bind the carcinomas efficiently and stay bound to the carcinomas over a prolonged time (i.e., at least 7 days).

Example 8

Fragmentation of Monoclonal Antibodies

Biodistribution studies both in animal models and in clinical trials have demonstrated that intact IgG may not be the best form of the antibody molecule to obtain optimal tumor localization with minimal background in normal organs. As a result, studies were undertaken to fragment the second generation monoclonal antibodies of the present invention and B72.3 with pepsin as described in Colcher, et al., Cancer Res., 43:736-742 (1983). The resulting fragments were radiolabelled with ^{125}I as described above and tested for binding specificity in a SPRIA as described above, using a LS-174T colon carcinoma cell extract. The results are shown in Table 5.

TABLE 5

Binding Specificity of Immunoreactive F(ab') ₂ Fragments	
F(ab') ₂ Fragment	Binding Specificity to LS-174T colon carcinoma cell extract
B72.3	<2%
CC 49	50%
CC 46	70%

As shown in Table 5, F(ab')₂ fragments of CC 49 were able to bind greater than 50% of the input counts in a SPRIA using limiting amounts of antigen and CC 46 fragments bound over 70% of the input activity while fragments obtained from B72.3 essentially lack all immunoreactivity, i.e., maintained less than 2% binding specificity.

A pharmaceutical composition comprising the second generation antibodies of the present invention in a pharmaceutically acceptable, non-toxic, sterile carrier such as physiological saline, non-toxic buffers and the like, now also becomes possible. The amount of said antibodies in the pharmaceutical composition should be sufficient to achieve effective binding with the antigens against which said antibodies have specific affinity or neutralization reactivity. The pharmaceutical composition may be administered in a single or multiple dosage with other adjuvants or additives, if necessary, in any suitable manner to the host in need of said antibodies.

Claim

1. An antibody, the antibody being a second generation monoclonal antibody, an immunoreactive fragment or a recombinant thereof, having a binding affinity for both TAG-72 and LS174T cell line antigen but without substantial binding affinity for normal adult human tissues wherein said antibody has a binding affinity of greater than $3 \times 10^9 \text{ M}^{-1}$ for TAG-72, and wherein said monoclonal antibody is obtainable from the hybridoma having the deposit accession number ATCC CRL 9459, from the hybridoma having the deposit accession number ATCC CRL 9453, from the hybridoma having the deposit accession number ATCC CRL 9454, from the hybridoma having the deposit accession number ATCC CRL 9455, from the hybridoma having the deposit accession number ATCC CRL 9456, from the hybridoma having the deposit accession number ATCC CRL 9457, from the hybridoma having the deposit accession number ATCC CRL 9458, from the hybridoma having the deposit accession number ATCC CRL 9460 or specifically binds to an epitope recognised by an antibody produced by any of said hybridomas.
2. An antibody according to claim 1, wherein the antibody has a binding affinity of greater than $8 \times 10^9 \text{ M}^{-1}$ for TAG-72.
3. An antibody according to claim 1 or 2, wherein the antibody has about 50% more efficiency than B72.3 antibody in targeting human carcinomas in situ.
4. An antibody according to any preceding claim wherein the antibody exhibits 0-30% competition with B72.3 for binding to LS-174 cell line antigens.

5. An antibody according to any preceding claim, the antibody having the IgG_{2a}, IgG_{2b}, IgG₃ or IgM isotype.
6. An antibody according to any preceding claim wherein the antibody is conjugated to a label, or a tumour detecting marker or to a therapeutic agent.
7. An antibody according to claim 6 wherein the label is a radioisotope, particularly ³²P, ¹⁴C, ³H, ¹²⁵I or ³⁵S, a fluorescent molecule, particularly fluorescein or rhodamine, or an enzyme, particularly alkaline phosphatase or horseradish peroxidase.
8. An antibody according to claim 6 wherein the label is ¹³¹I, ¹²³I, ¹¹¹In, ⁶⁷Ga, ^{99m}Tc or Gd.
9. An antibody according to claim 6 wherein the label is a radionuclide, particularly ¹³¹I, ⁹⁰Y, ¹⁰⁵Rh, ⁴⁷Sc, ⁶⁷Cu, ²¹²Bi or ²¹¹At, a toxin, a drug, particularly methotrexate or adriamycin, or a second antibody, particularly one which has specific binding affinity to killer T-cells.
10. An antibody according to any preceding claim, conjugated to an imaging or detecting marker.
11. An antibody according to any of claims 1 to 9 for use to destroy or inhibit growth and proliferation of a carcinoma or metastases thereof.
12. A method for detecting a human carcinoma or metastases thereof in a biopsy or a sample of body fluid, preferably blood, plasma, serum, nipple discharge, cyst fluid, ascites fluids, pleural effusions, seminal plasma, semen, urine or prostatic fluid, the method comprising:
 - (a) contacting the body fluid or biopsy with an antibody according to any previous claim;
 - (b) determining the amount of binding of antibody to the body fluid or biopsy material, preferably by immunoassay, particularly enzyme or radio-immunoassay; and
 - (c) comparing the amount of binding in step (b) to a control sample or to a predetermined base level;a binding greater than the base level being indicative of the presence of carcinomas or metastases thereof.
13. A pharmaceutical composition comprising a pharmaceutically effective amount of an antibody according to any of claims 1 to 11, and a pharmaceutically acceptable, non-toxic, sterile carrier.
14. Use of an antibody according to any of claims 1 to 11 for preparing a pharmaceutical composition for use in the induction of production of anti-idiotypic antibodies against a tumour of a cancer patient.
15. An antibody according to any one of claims 1 to 11, for use in therapy or diagnosis or detection of carcinomas.
16. A hybridoma having one of the deposit accession numbers ATCC No. HB-9459 ATCC No. 9453, ATCC No. HB-9454, ATCC No. HB-9456, ATCC No. HB-9457, ATCC No. HB-9458 or ATCC No. HB-9460, which produces a second generation monoclonal antibody having specific binding affinity to both TAG-72 and LS174T antigens without substantial binding affinity to normal adult human tissues, wherein said monoclonal antibody has a binding affinity of greater than $3 \times 10^9 \text{ M}^{-1}$ for TAG-72, and wherein said monoclonal antibody is obtainable from the hybridoma, or specifically binds to an epitope recognised by CC49, CCB3, CC92, CC11, MATAG 12, CC30, CC45 or CC15.

Patentansprüche

1. Antikörper, wobei der Antikörper ein monoklonaler Antikörper der zweiten Generation ist, ein immunreaktives Fragment oder eine Rekombinante davon, mit einer Bindungsaffinität sowohl für das TAG-72 wie auch LS174T Zelllinientantigene aber ohne wesentliche Bindungsaffinität für normale menschliche Erwachsenengewebe, wobei der Antikörper eine Bindungsaffinität von mehr als $3 \times 10^9 \text{ M}^{-1}$ für TAG-72 hat, und wobei der monoklonale Antikörper aus dem Hybridom mit der Eingangsnummer ATCC CRL 9459, aus dem Hybridom mit der Eingangsnummer ATCC CRL 9453, aus dem Hybridom mit der Eingangsnummer ATCC CRL 9454, aus dem Hybridom mit der Eingangsnummer ATCC CRL 9455, aus dem Hybridom mit der Eingangsnummer ATCC CRL 9456, aus dem Hybridom mit der Eingangsnummer ATCC CRL 9457, aus dem Hybridom mit der Eingangsnummer ATCC CRL 9458, aus dem

Hybridom mit der Eingangsnummer ATCC CRL 9460 erhältlich ist, oder spezifisch an ein Epitop bindet, das durch einen durch eines der Hybridome hergestellten Antikörper erkannt wird.

2. Antikörper nach Anspruch 1, wobei der Antikörper eine Bindungsaffinität von mehr als $8 \times 10^9 \text{ M}^{-1}$ für TAG-72 hat.
3. Antikörper nach Anspruch 1 oder 2, wobei der Antikörper etwa 50% mehr Effizienz als B72,3 Antikörper beim Auffangen von menschlichen Karzinomen in situ hat.
4. Antikörper nach einem vorhergehenden Anspruch, wobei der Antikörper 0-30% Konkurrenz mit B72,3 in Bezug auf das Binden an LS-174T Zelllinienantigene zeigt.
5. Antikörper nach einem vorhergehenden Anspruch, wobei der Antikörper das IgG_{2a}, IgG_{2b}, IgG₃ oder IgM Isotyp hat.
6. Antikörper nach einem vorhergehenden Anspruch, wobei der Antikörper an eine Markierung oder einen tumormachweisenden Marker oder ein therapeutisches Mittel konjugiert ist.
7. Antikörper nach Anspruch 6, wobei die Markierung ein Radioisotop, insbesondere ³²P, ¹⁴C, ³H, ¹²⁵I oder ³⁵S, ein fluoreszierendes Molekül, insbesondere Fluorescein oder Rhodamin, oder ein Enzym, insbesondere alkalische Phosphatase oder Meerrettichperoxidase ist.
8. Antikörper nach Anspruch 6, wobei die Markierung ¹³¹I, ¹²⁵I, ¹¹¹In, ⁶⁷Ga, ^{99m}Tc oder Gd ist.
9. Antikörper nach Anspruch 6, wobei die Markierung ein radioaktives Nuclid, insbesondere ¹³¹I, ⁹⁰Y, ¹⁰⁵Rh, ⁴⁷Sc, ⁶⁷Cu, ²¹²Bi oder ²¹¹At, ein Toxin, ein Arzneimittel, insbesondere Methotrexat oder Adriamycin, oder ein zweiter Antikörper, insbesondere einer, welcher spezifische Bindungsaffinität an Killer T-Zellen hat, ist.
10. Antikörper nach einem vorhergehenden Anspruch, konjugiert an einen bildgebenden oder Nachweismarker.
11. Antikörper nach einem der Ansprüche 1 bis 9 für die Verwendung zum Zerstören oder Inhibieren von Wachstum und Vermehrung eines Karzinoms oder Metastasen davon.
12. Verfahren zum Nachweisen eines menschlichen Karzinoms oder Metastasen davon bei einer Biopsie oder in einer Probe von Körperflüssigkeit, vorzugsweise Blut, Plasma, Serum, Brustwarzensekret, Zystenflüssigkeit, Aszitesflüssigkeiten, Pleuraexsudaten, Spermaplasma, Sperma, Urin oder Prostataflüssigkeit, wobei das Verfahren umfaßt:
 - (a) in Berührungbringen der Körperflüssigkeit oder Biopsie mit einem Antikörper gemäß einem vorhergehenden Anspruch;
 - (b) Bestimmen der Bindungsmenge des Antikörpers an die Körperflüssigkeit oder das Biopsiematerial, vorzugsweise durch Immunassay, insbesondere Enzym- oder Radioimmunassay; und
 - (c) Vergleichen der Bindungsmenge in Stufe (b) mit einer Kontrollprobe oder einem zuvor festgelegten Grundniveau;wobei eine Bindung größer als das Grundniveau das Vorhandensein von Karzinomen oder Metastasen davon anzeigt.
13. Pharmazeutische Zusammensetzung umfassend eine pharmazeutisch wirksame Menge eines Antikörpers nach einem der Ansprüche 1 bis 11 und einen pharmazeutisch verträglichen, nichttoxischen, sterilen Träger.
14. Verwendung eines Antikörpers nach einem der Ansprüche 1 bis 11 zum Herstellen einer pharmazeutischen Zusammensetzung für die Verwendung bei der Induktion der Herstellung von antiidiotypischen Antikörpern gegen einen Tumor eines Krebspatienten.
15. Antikörper nach einem der Ansprüche 1 bis 11 für die Verwendung bei der Therapie oder Diagnose oder dem Nachweis von Karzinomen.
16. Hybridom mit einer der Eingangsnummern ATCC Nr. HB-9459, ATCC Nr. HB-9453, ATCC Nr. HB-9454, ATCC Nr.

HB-9456, ATCC Nr. HB-9457, ATCC Nr. HB-9458 oder ATCC Nr. HB-9460, welches einen monoklonalen Antikörper der zweiten Generation mit einer spezifischen Bindungsaffinität sowohl an TAG-72 wie auch LS174T Antigene ohne wesentliche Bindungsaffinität an normale menschliche Erwachsenengewebe erzeugt, wobei der monoklonale Antikörper eine Bindungsaffinität von größer als $3 \times 10^9 \text{ M}^{-1}$ für TAG-72 hat, und wobei der monoklonale Antikörper aus dem Hybridom erhältlich ist oder spezifisch an ein durch CC49, CC83, CC92, CC11, MATAG 12, CC30, CC45 oder CC15 erkanntes Epitop bindet.

Revendications

1. Anticorps, ledit anticorps étant un anticorps monoclonal de seconde génération, un fragment immunoréactif ou un recombinant de celui-ci, ayant une affinité de liaison tant pour TAG-72 que pour les antigènes de la lignée cellulaire LS174T mais sans affinité de liaison notable pour des tissus humains adultes normaux, où ledit anticorps possède une affinité de liaison supérieure à $3 \times 10^9 \text{ M}^{-1}$ pour TAG-72, et où ledit anticorps monoclonal peut s'obtenir à partir de l'hybridome ayant le numéro d'ordre de dépôt ATCC CRL 9459, à partir de l'hybridome ayant le numéro d'ordre de dépôt ATCC CRL 9453, à partir de l'hybridome ayant le numéro d'ordre de dépôt ATCC CRL 9454, à partir de l'hybridome ayant le numéro d'ordre de dépôt ATCC CRL 9455, à partir de l'hybridome ayant le numéro d'ordre de dépôt ATCC CRL 9456, à partir de l'hybridome ayant le numéro d'ordre de dépôt ATCC CRL 9457, à partir de l'hybridome ayant le numéro d'ordre de dépôt ATCC CRL 9458, à partir de l'hybridome ayant le numéro d'ordre de dépôt ATCC CRL 9460, ou se lie spécifiquement à un épitope reconnu par un anticorps produit par n'importe lequel desdits hybridomes.
2. Anticorps selon la revendication 1, ledit anticorps possédant une affinité de liaison supérieure à $8 \times 10^9 \text{ M}^{-1}$ pour TAG-72.
3. Anticorps selon la revendication 1 ou 2, ledit anticorps ayant environ 50% d'efficacité en plus que l'anticorps B72.3 dans le ciblage de carcinomes humains in situ.
4. Anticorps selon l'une quelconque des revendications précédentes, ledit anticorps présentant de 0 à 30% de compétition avec B72.3 pour la liaison aux antigènes de la lignée cellulaire LS-174T.
5. Anticorps selon l'une quelconque des revendications précédentes, ledit anticorps ayant l'isotype IgG_{2a}, IgG_{2b}, IgG₃ ou IgM.
6. Anticorps selon l'une quelconque des revendications précédentes, ledit anticorps étant conjugué à un traceur, ou à un marqueur de détection de tumeurs ou à un agent thérapeutique.
7. Anticorps selon la revendication 6, où le traceur est un radioisotope, en particulier ³²P, ¹⁴C, ³H, ¹²⁵I ou ³⁵S, une molécule fluorescente, en particulier la fluorescéine ou la rhodamine, ou une enzyme, en particulier la phosphatase alcaline ou la peroxydase de raifort.
8. Anticorps selon la revendication 6, où le traceur est ¹³¹I, ¹²³I, ¹¹¹In, ⁶⁷Ga, ^{99m}Tc ou Gd.
9. Anticorps selon la revendication 6, où le traceur est un radionucléide, en particulier ¹³¹I, ⁹⁰Y, ¹⁰⁵Rh, ⁴⁷Sc, ⁶⁷Cu, ²¹²Pb ou ²¹¹At, une toxine, un médicament, en particulier le méthotrexate ou l'adriamycine, ou un deuxième anticorps, en particulier un qui possède une affinité de liaison spécifique pour les lymphocytes T tueurs.
10. Anticorps selon l'une quelconque des revendications précédentes, conjugué à un marqueur d'imagerie ou de détection.
11. Anticorps selon l'une quelconque des revendications 1 à 9 destiné à être utilisé pour détruire ou inhiber la croissance et la prolifération d'un carcinome ou de métastases de ce dernier.
12. Procédé de détection d'un carcinome humain ou de métastases de ce dernier dans une biopsie ou un échantillon de fluide corporel, de préférence le sang, le plasma, le sérum, l'écoulement mammaire, le liquide de kyste, les liquides d'ascites, les liquides d'épanchement pleural, le plasma séminal, le sperme, l'urine ou le liquide prostatique, ledit procédé comportant:

- (a) la mise en contact du fluide corporel ou de la biopsie avec un anticorps selon l'une quelconque des revendications précédentes;
- (b) la mesure du niveau de liaison de l'anticorps au fluide corporel ou à la matière biopsique, de préférence par immunodosage, en particulier par enzymo- ou radioimmunodosage; et
- (c) la comparaison du niveau de liaison de l'étape (b) à un échantillon témoin ou à un niveau de base prédéterminé;

une liaison supérieure au niveau de base reflétant la présence de carcinomes ou de métastases de ceux-ci.

13. Composition pharmaceutique comprenant une quantité efficace sur le plan pharmaceutique d'un anticorps selon l'une quelconque des revendications 1 à 11, et un support pharmaceutiquement acceptable non toxique et stérile.
14. Utilisation d'un anticorps selon l'une quelconque des revendications 1 à 11 pour préparer une composition pharmaceutique destinée à être utilisée dans l'induction de la production d'anticorps anti-idiotypes dirigés contre une tumeur d'un patient cancéreux.
15. Anticorps selon l'une quelconque des revendications 1 à 11 destiné à être utilisé dans le traitement, le diagnostic ou la détection de carcinomes.
16. Hybridome ayant l'un des numéros d'ordre de dépôt parmi ATCC HB-9459, ATCC HB-9453, ATCC HB-9454, ATCC HB-9456, ATCC HB-9457, ATCC HB-9458 ou ATCC HB-9460, qui produit un anticorps monoclonal de seconde génération possédant une affinité de liaison spécifique tant pour TAG-72 que pour les antigènes de LS174T sans affinité de liaison notable pour des tissus humains adultes normaux, où ledit anticorps monoclonal possède une affinité de liaison supérieure à $3 \times 10^9 \text{ M}^{-1}$ pour TAG-72, et où ledit anticorps monoclonal peut s'obtenir à partir dudit hybridome, ou se lie spécifiquement à un épitope reconnu par CC49, CC83, CC92, CC11, MATAG 12, CC30, CC45 ou CC15.









Figure 1




Ab DILUTION (1 : 5)

Fig. 2E




1/Ab DILUTION

Fig. 2F




1/Ab DILUTION

Fig. 2G



1/Ab DILUTION

Fig. 2H



1/Ab DILUTION

Ab DILUTION (1 : 5)

Figure 3




Fig. 4A




Fig. 4B

